Università Cattolica del Sacro Cuore, Largo A. Gemelli, n. 8 – 00168 – Rome (Italy)
Dermatology and Venereology
– Type of employment Physician specializing in Dermatology and Venereology
– Main duties and responsibilities – Clinical and research activities inherent to the main areas of dermatology (dermatology
inflammatory, oncologic dermatology, pediatric dermatology)
– Oncologic and reconstructive dermo-surgical activities
Has participated as a speaker or participant in national and international conferences in
Dermatologic field.
Member of the Italian Society of Medical, Surgical, and Aesthetic Dermatology and Diseases
Sexually Transmitted Diseases (SIDeMaST).
Author of scientific publications in national and international journals:.
[ 2020 ] Baricitinib: therapeutic potential for moderate to severe atopic dermatitisCalabrese L, Malvaso D, Chiricozzi A, et al. Baricitinib: therapeutic potential for moderate to severe atopic dermatitis
Moderate to severe atopic dermatitis [published online August 14, 2020]. Expert opinions.
Investig Drugs. 2020;1-10. [Clinical and ultrasonographic profile of patients with suppurative hydradenitis treated with Adalimumab.
Suppurative
Chiricozzi A, Giovanardi G, Garcovich S, et al. Clinical and ultrasonographic profile of patients with Hidradenitis Suppurativa treated with Adalimumab.
Patients with Hidradenitis Suppurativa treated with Adalimumab: A single-center real-world experience.
Single-center real-world experience. Acta Derm Venereol. 2020;100(13):adv00172. Published 2020 Jun 11.
[2020] Apremilast for the treatment of hidradenitis suppurativa associated with
psoriatic arthritis
Garcovich S, Giovanardi G, Malvaso D, De Simone C, Peris K. Apremilast for the treatment of hidradenitis suppurativa associated with psoriatic arthritis.
Of hidradenitis suppurativa associated with psoriatic arthritis in multimorbid patients:
Case report and review of the literature. Medicine (Baltimore). 2020;99(5):e18991.
hidradenitis suppurativa and systemic lupus erythematosus.
Giovanardi G, Peris K. Occurrence of COVID-19 in a secukinumab-treated patient with hidradenitis suppurativa and systemic lupus erythematosus.
By hidradenitis suppurativa and systemic lupus erythematosus. Int J Dermatol. 2020 Sep
23:10.1111/ijd.15209. [Prevalence of neuropathic pain and related features in hidradenitis suppurativa.
Suppurative: A cross-sectional study
Garcovich S, Muratori S, Moltrasio C, Buscemi AA, Giovanardi G, Malvaso D, Di Stasio E,
Marzano AV, Peris K. Prevalence of neuropathic pain and related features in the
Hidradenitis Suppurativa: A Cross-Sectional Study. J Clin Med. 2020 Dec 15;9(12):4046. [2021] Successful combination of systemic agents for the treatment of Dupilicus-resistant atopic dermatitis.
Atopic Dermatitis Resistant to Dupilumab Therapy.
Gori N, Chiricozzi A, Malvaso D, D’Urso DF, Caldarola G, De Simone C, Peris K. Successful combination of systemic agents for the treatment of atopic dermatitis resistant to Dupilumab therapy.
Combination of systemic agents for the treatment of atopic dermatitis resistant to Dupilumab therapy.
Dupilumab. Dermatology. 2021 Jan 21:1-7. [PASH, PAPASH, PsPASH and PASS: the autoinflammatory syndromes of hidradenitis suppurativa.
hidradenitis suppurativa
Garcovich S, Genovese G, Moltrasio C, Malvaso D, Marzano AV. PASH, PAPASH, PsPASH
and PASS: the autoinflammatory syndromes of hidradenitis suppurativa. Clin Dermal
Published 16, October 2020 [2021] Relapses as a dynamic predictor of adalimumab response in hidradenitis suppurativa.
hidradenitis suppurativa, real-life data
Caposiena C, Chiricozzi A, Sechi A, Molinelli E, Venturini M, Candi E, Malvaso D, Peris K,
Patrizi A, Offidani A, Pinton P, Bianchi L (May 2021). Eruptions as a dynamic predictor of
response to adalimumab in suppurative hidradenitis, real-world data. Italian Journal of
Dermatology and Venereology.
